Table 4 Base case analysis results
Health outcomes | PIONEER 2 | ||
|---|---|---|---|
Oral semaglutide 14Â mg | Empagliflozin 25Â mg | Difference | |
Discounted life expectancy (years) | 12.47 (0.16) | 12.37 (0.17) | + 0.10 |
Discounted quality-adjusted life expectancy (QALYs) | 8.16 (0.11) | 8.05 (0.11) | + 0.11 |
Discounted direct costs (EUR) | 25,930 (532) | 23,382 (542) | + 2548 |
ICER based on direct costs | EUR 23,571 per QALY gained | ||
Health outcomes | NMA | ||
|---|---|---|---|
Oral semaglutide 14Â mg | Dulaglutide 1.5Â mg | Difference | |
Discounted life expectancy (years) | 12.02 (0.16) | 11.99 (0.18) | + 0.03 |
Discounted quality-adjusted life expectancy (QALYs) | 7.78 (0.11) | 7.75 (0.12) | + 0.03 |
Discounted direct costs (EUR) | 26,626 (612) | 25,812 (619) | + 814 |
ICER based on direct costs | EUR 23,927 per QALY gained | ||